INTS (Intensity Therapeutics) PS Ratio: (As of Jul. 01, 2026)


INTS Intensity Therapeutics Inc INTS
28 GF Score
Price $4.15
! 1 Warning Sign
View Full Analysis

What is Intensity Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Intensity Therapeutics's share price is $4.15. Intensity Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00. Hence, Intensity Therapeutics's PS Ratio for today is .

The historical rank and industry rank for Intensity Therapeutics's PS Ratio or its related term are showing as below:

INTS's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.515
* Ranked among companies with meaningful PS Ratio only.

Intensity Therapeutics's Revenue per Sharefor the three months ended in Mar. 2026 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00.

Back to Basics: PS Ratio


Intensity Therapeutics  (NAS:INTS) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Intensity Therapeutics PS Ratio Related Terms


Intensity Therapeutics PS Ratio Historical Data

* Premium members only.

The historical data trend for Intensity Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intensity Therapeutics PS Ratio Chart

Intensity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PS Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Intensity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

INTS vs KPRX, PHIO, PBM: PS Ratio Comparison

For the Biotechnology subindustry, Intensity Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intensity Therapeutics PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intensity Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Intensity Therapeutics's PS Ratio falls into.


INTS
28GF Score
Intensity Therapeutics Inc INTS
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intensity Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Intensity Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=4.15/0
=

Intensity Therapeutics's Share Price of today is $4.15.
Intensity Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Intensity Therapeutics Business Description

Address 1 Enterprise Drive, Suite 430, Shelton, CT, USA, 06484-4779
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
28GF Score

Get the complete analysis for INTS

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.15
Price